Ariad Pharmaceuticals Inc (ARIA): Timothy P Clackson , President, R&D, CSO of Ariad Pharmaceuticals Inc sold 61,422 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $7.48 per share for a total value of $459,633.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 29, 2016, Hugh M Cole (SVP, Chief Business Officer) sold 6,012 shares at $7.05 per share price.On Jun 23, 2016, Timothy P Clackson (President, R&D, CSO) sold 23,999 shares at $7.28 per share price.Also, On Jun 15, 2016, Athanese Lavidas (director) sold 76,250 shares at $8.20 per share price.On Jun 14, 2016, Massimo Radaelli (director) sold 108,569 shares at $8.23 per share price.
Ariad Pharmaceuticals: On Friday, Jul 1, 2016 heightened volatility was witnessed in Ariad Pharmaceuticals which led to swings in the share price. The shares opened for trading at $7.36 and hit $7.6599 on the upside , eventually ending the session at $7.49, with a gain of 1.35% or 0.1 points. The heightened volatility saw the trading volume jump to 22,44,666 shares. The 52-week high of the share price is $10.07 and the company has a market cap of $1,432 M . The 52-week low of the share price is at $4.37.
Company has been under the radar of several Street Analysts.Ariad Pharmaceuticals is Reiterated by Barclays to Underweight and the brokerage firm has raised the Price Target to $ 8 from a previous price target of $6 .The Rating was issued on May 11, 2016.
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).